TrialInternational journal of hematology2023

A phase 2 study of axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma in Japan: 1-year follow-up and biomarker analysis.

Koji Kato et al.PubMed ↗Publisher ↗

No numbers read from the abstract.